Eli Lilly and Co (LLY.US) explores new uses for 'weight-loss miracle drug' Zepbound, aiming to reduce the incidence of high-risk populations such as diabetes.
eli lilly and co is exploring new uses for its weight loss drug Zepbound to reduce the incidence of diabetes in high-risk populations, even if they are not overweight.
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
New Small-cap Buy and Sell Ideas for Oppenheimer's 50/50 List
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Morgan Stanley Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $105
$100 Invested In Viking Therapeutics 5 Years Ago Would Be Worth This Much Today